Your browser doesn't support javascript.
loading
Cerebral quantitative susceptibility mapping predicts amyloid-ß-related cognitive decline.
Ayton, Scott; Fazlollahi, Amir; Bourgeat, Pierrick; Raniga, Parnesh; Ng, Amanda; Lim, Yen Ying; Diouf, Ibrahima; Farquharson, Shawna; Fripp, Jurgen; Ames, David; Doecke, James; Desmond, Patricia; Ordidge, Roger; Masters, Colin L; Rowe, Christopher C; Maruff, Paul; Villemagne, Victor L; Salvado, Olivier; Bush, Ashley I.
Afiliação
  • Ayton S; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
  • Fazlollahi A; CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
  • Bourgeat P; Cooperative Research Centre for Mental Health, Parkville, Australia.
  • Raniga P; CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
  • Ng A; Cooperative Research Centre for Mental Health, Parkville, Australia.
  • Lim YY; CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
  • Diouf I; Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Australia.
  • Farquharson S; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
  • Fripp J; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
  • Ames D; CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
  • Doecke J; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
  • Desmond P; Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Australia.
  • Ordidge R; CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
  • Masters CL; Cooperative Research Centre for Mental Health, Parkville, Australia.
  • Rowe CC; National Ageing Research Institute, Parkville, Victoria, Australia.
  • Maruff P; University of Melbourne Academic Unit for the Psychiatry of Old Age, Parkville, Australia.
  • Villemagne VL; CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, Australia.
  • Salvado O; Department of Medicine and Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
  • Bush AI; Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Australia.
Brain ; 140(8): 2112-2119, 2017 Aug 01.
Article em En | MEDLINE | ID: mdl-28899019
ABSTRACT
See Derry and Kent (doi10.1093/awx167) for a scientific commentary on this article.The large variance in cognitive deterioration in subjects who test positive for amyloid-ß by positron emission tomography indicates that convergent pathologies, such as iron accumulation, might combine with amyloid-ß to accelerate Alzheimer's disease progression. Here, we applied quantitative susceptibility mapping, a relatively new magnetic resonance imaging method sensitive to tissue iron, to assess the relationship between iron, amyloid-ß load, and cognitive decline in 117 subjects who underwent baseline magnetic resonance imaging and amyloidpositron emission tomography from the Australian Imaging, Biomarkers and Lifestyle study (AIBL). Cognitive function data were collected every 18 months for up to 6 years from 100 volunteers who were either cognitively normal (n = 64) or diagnosed with mild cognitive impairment (n = 17) or Alzheimer's disease (n = 19). Among participants with amyloid pathology (n = 45), higher hippocampal quantitative susceptibility mapping levels predicted accelerated deterioration in composite cognition tests for episodic memory [ß(standard error) = -0.169 (0.034), P = 9.2 × 10-7], executive function [ß(standard error) = -0.139 (0.048), P = 0.004), and attention [ß(standard error) = -0.074 (0.029), P = 0.012]. Deteriorating performance in a composite of language tests was predicted by higher quantitative susceptibility mapping levels in temporal lobe [ß(standard error) = -0.104 (0.05), P = 0.036] and frontal lobe [ß(standard error) = -0.154 (0.055), P = 0.006]. These findings indicate that brain iron might combine with amyloid-ß to accelerate clinical progression and that quantitative susceptibility mapping could be used in combination with amyloidpositron emission tomography to stratify individuals at risk of decline.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lobo Temporal / Peptídeos beta-Amiloides / Doença de Alzheimer / Disfunção Cognitiva / Lobo Frontal / Hipocampo / Ferro Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lobo Temporal / Peptídeos beta-Amiloides / Doença de Alzheimer / Disfunção Cognitiva / Lobo Frontal / Hipocampo / Ferro Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article